US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Procaps

1.01

0.0000

Volume:- -

Turnover:- -

Market Cap:113.95M

PE:1.96

High:1.01

Open:1.01

Low:1.01

Close:1.01

52wk High:3.84

52wk Low:0.5000

Shares:112.82M

Float Shares:19.15M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.5158

EPS(LYR):0.4207

ROE:373.70%

ROA:6.28%

PB:2.89

PE(LYR):2.40

Loading ...

Overview Company News Filings

Sonnet Releases Virtual Investor "What This Means" Segment

Immunocore reports second quarter financial results and provides a business update

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

AbbVie Reports First-Quarter 2025 Financial Results

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sonnet Announces Release of Corporate Update Video

Press Release: Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Press Release: Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Press Release: MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PROC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PROC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PROC\",,,,,undefined,":{"symbol":"PROC","market":"US","secType":"STK","nameCN":"Procaps","latestPrice":1.01,"timestamp":1755547200000,"preClose":1.01,"halted":4,"volume":0,"delay":0,"floatShares":19147990,"shares":112824183,"eps":0.515793,"marketStatus":"Delisted","change":0,"latestTime":"08-18 17:38:29 EDT","open":1.01,"high":1.01,"low":1.01,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.515793,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1755561600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.01,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PROC\",,,,,undefined,":{"symbol":"PROC","floatShares":19147990,"roa":"6.28%","roe":"373.70%","lyrEps":0.420729,"shares":112824183,"dividePrice":0,"high":1.01,"amplitude":0,"preClose":1.01,"low":1.01,"week52Low":0.5,"pbRate":"2.89","psRate":"0.28","week52High":3.84,"institutionHeld":0,"latestPrice":1.01,"eps":0.515793,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.515793,"open":1.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PROC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"PROC","reason":null,"defaultRemindTime":1738679400000,"announcedDate":"2025-02-03","type":"delisting","dateTimestamp":1738645200000},{"market":"US","date":"2023-12-26","symbol":"PROC","fiscalQuarterEnding":"2023/09","expectedEps":0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1703566800000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2023-09-05","symbol":"PROC","fiscalQuarterEnding":"2023/06","expectedEps":0.06,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1693886400000,"reportTimeType":"pre","actualEps":0.27}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PROC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PROC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1694062800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PROC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PROC","date":"2025-01-31","current":3.436401,"percent":0.376079,"low":-132.08308,"twenty":-14.467484,"median":4.777205,"eighty":8.574248,"high":15.174275,"avg":-17.238194,"sd":45.468463,"marketCap":179390450},"quantilePoints":[{"date":"2021-10-01","current":-103.67686,"twenty":-108.860703,"median":-106.916762,"eighty":-104.972821,"marketCap":1083112156},{"date":"2021-10-08","current":-108.752706,"twenty":-108.752706,"median":-107.996729,"eighty":-104.540834,"marketCap":1136139522},{"date":"2021-10-15","current":-104.216844,"twenty":-108.601511,"median":-104.378839,"eighty":-103.784857,"marketCap":1088753365},{"date":"2021-10-22","current":-109.832674,"twenty":-109.61668,"median":-104.540834,"eighty":-102.985681,"marketCap":1147421941},{"date":"2021-10-29","current":-112.316598,"twenty":-109.61668,"median":-105.890793,"eighty":-103.784857,"marketCap":1173371503},{"date":"2021-11-05","current":-107.996729,"twenty":-109.61668,"median":-106.484775,"eighty":-104.216844,"marketCap":1128241830},{"date":"2021-11-12","current":-111.236631,"twenty":-109.61668,"median":-106.214783,"eighty":-104.216844,"marketCap":1162089084},{"date":"2021-11-19","current":-9.268173,"twenty":-108.752706,"median":-106.484775,"eighty":-104.216844,"marketCap":1106805235},{"date":"2021-11-26","current":-121.140525,"twenty":-109.832674,"median":-106.484775,"eighty":-104.216844,"marketCap":1061675562},{"date":"2021-12-03","current":-127.062379,"twenty":-111.236631,"median":-106.808765,"eighty":-104.216844,"marketCap":1113574686},{"date":"2021-12-10","current":-128.735946,"twenty":-121.140525,"median":-107.456745,"eighty":-104.216844,"marketCap":1128241830},{"date":"2021-12-17","current":-113.931312,"twenty":-120.239373,"median":-108.050727,"eighty":-104.540834,"marketCap":998494019},{"date":"2021-12-23","current":-123.329036,"twenty":-122.505126,"median":-108.482715,"eighty":-105.059218,"marketCap":1080855673},{"date":"2021-12-31","current":-125.517547,"twenty":-123.354783,"median":-109.832674,"eighty":-105.275212,"marketCap":1100035784},{"date":"2022-01-07","current":-119.72443,"twenty":-123.560761,"median":-110.804644,"eighty":-105.296811,"marketCap":1049264901},{"date":"2022-01-14","current":-117.79339,"twenty":-123.354783,"median":-112.316598,"eighty":-105.469605,"marketCap":1032341274},{"date":"2022-01-21","current":-117.535919,"twenty":-123.38053,"median":-113.931312,"eighty":-105.707199,"marketCap":1030084790},{"date":"2022-01-28","current":-120.110637,"twenty":-123.251794,"median":-116.184191,"eighty":-105.85429,"marketCap":1052649627},{"date":"2022-02-04","current":-122.299149,"twenty":-123.123058,"median":-117.664654,"eighty":-105.913256,"marketCap":1071829738},{"date":"2022-02-11","current":-114.9612,"twenty":-122.994322,"median":-117.664654,"eighty":-106.203983,"marketCap":1007519954},{"date":"2022-02-18","current":-102.602549,"twenty":-122.556621,"median":-117.535919,"eighty":-105.913256,"marketCap":899208738},{"date":"2022-02-25","current":-115.991087,"twenty":-122.299149,"median":-115.991087,"eighty":-105.897489,"marketCap":1016545888},{"date":"2022-03-04","current":-121.655469,"twenty":-122.299149,"median":-116.634767,"eighty":-106.101231,"marketCap":1066188529},{"date":"2022-03-11","current":-115.476143,"twenty":-122.299149,"median":-116.763503,"eighty":-106.352246,"marketCap":1012032921},{"date":"2022-03-18","current":-108.395666,"twenty":-122.299149,"median":-115.926719,"eighty":-106.352246,"marketCap":949979620},{"date":"2022-03-25","current":-114.31752,"twenty":-122.299149,"median":-115.733615,"eighty":-106.419977,"marketCap":1001878745},{"date":"2022-04-01","current":-108.524402,"twenty":-122.299149,"median":-114.9612,"eighty":-106.527974,"marketCap":951107862},{"date":"2022-04-08","current":-109.425554,"twenty":-122.299149,"median":-114.31752,"eighty":-106.63597,"marketCap":959005555},{"date":"2022-04-14","current":-102.988757,"twenty":-122.247655,"median":-112.532592,"eighty":-106.344068,"marketCap":902593464},{"date":"2022-04-22","current":-102.988757,"twenty":-122.01593,"median":-111.807813,"eighty":-105.881721,"marketCap":902593464},{"date":"2022-04-29","current":-102.988757,"twenty":-121.861447,"median":-110.912641,"eighty":-105.577602,"marketCap":902593464},{"date":"2022-05-06","current":-8.389413,"twenty":-121.655469,"median":-110.70478,"eighty":-104.870611,"marketCap":846181372},{"date":"2022-05-13","current":-8.614026,"twenty":-121.55248,"median":-109.832674,"eighty":-104.216844,"marketCap":868836468},{"date":"2022-05-20","current":-8.814477,"twenty":-121.114778,"median":-109.489922,"eighty":-103.71947,"marketCap":889054562},{"date":"2022-05-27","current":-8.959893,"twenty":-120.960295,"median":-109.425554,"eighty":-103.040251,"marketCap":903721705},{"date":"2022-06-03","current":-10.514843,"twenty":-120.754317,"median":-109.425554,"eighty":-102.812886,"marketCap":1060558602},{"date":"2022-06-10","current":-10.112039,"twenty":-120.239373,"median":-109.425554,"eighty":-101.408929,"marketCap":1019930614},{"date":"2022-06-17","current":-14.275795,"twenty":-120.110637,"median":-109.425554,"eighty":-14.897944,"marketCap":957877313},{"date":"2022-06-24","current":-14.460758,"twenty":-119.90466,"median":-108.752706,"eighty":-14.460758,"marketCap":970287973},{"date":"2022-07-01","current":-14.309425,"twenty":-119.853166,"median":-108.331299,"eighty":-14.460758,"marketCap":960133797},{"date":"2022-07-08","current":-14.763426,"twenty":-119.775924,"median":-108.158725,"eighty":-14.470847,"marketCap":990596326},{"date":"2022-07-15","current":-14.696166,"twenty":-119.72443,"median":-107.996729,"eighty":-14.47421,"marketCap":986083359},{"date":"2022-07-22","current":-14.29261,"twenty":-119.415464,"median":-107.47563,"eighty":-14.460758,"marketCap":959005555},{"date":"2022-07-29","current":-13.788165,"twenty":-119.209486,"median":-106.916762,"eighty":-14.34978,"marketCap":925158300},{"date":"2022-08-05","current":-12.863349,"twenty":-119.132244,"median":-106.64677,"eighty":-14.215262,"marketCap":863104999},{"date":"2022-08-12","current":-13.334165,"twenty":-118.926267,"median":-106.464627,"eighty":-13.989943,"marketCap":894695771},{"date":"2022-08-19","current":-12.871757,"twenty":-118.591553,"median":-106.356335,"eighty":-13.785878,"marketCap":863669120},{"date":"2022-08-26","current":-12.577497,"twenty":-118.43707,"median":-105.944791,"eighty":-13.145838,"marketCap":843924888},{"date":"2022-09-02","current":-11.241206,"twenty":-118.282587,"median":-105.6748,"eighty":-12.917157,"marketCap":824744777},{"date":"2022-09-09","current":-11.225828,"twenty":-118.128104,"median":-105.296811,"eighty":-12.678386,"marketCap":823616535},{"date":"2022-09-16","current":-10.718359,"twenty":-117.947873,"median":-104.79106,"eighty":-12.27483,"marketCap":786384555},{"date":"2022-09-23","current":-10.449247,"twenty":-117.79339,"median":-104.378839,"eighty":-11.419589,"marketCap":766640323},{"date":"2022-09-30","current":-10.764492,"twenty":-117.79339,"median":-104.216844,"eighty":-11.225828,"marketCap":789769281},{"date":"2022-10-07","current":-10.249335,"twenty":-117.741896,"median":-103.783384,"eighty":-11.179695,"marketCap":751973179},{"date":"2022-10-14","current":-10.149379,"twenty":-117.664654,"median":-103.246229,"eighty":-10.856759,"marketCap":744639607},{"date":"2022-10-21","current":-10.764492,"twenty":-117.61316,"median":-102.988757,"eighty":-10.736812,"marketCap":789769281},{"date":"2022-10-28","current":-10.472313,"twenty":-117.535919,"median":-102.812886,"eighty":-10.673394,"marketCap":768332686},{"date":"2022-11-04","current":-10.795248,"twenty":-117.226953,"median":-101.958869,"eighty":-10.656848,"marketCap":792025764},{"date":"2022-11-11","current":-10.764492,"twenty":-116.660514,"median":-100.868945,"eighty":-10.656848,"marketCap":789769281},{"date":"2022-11-18","current":12.895158,"twenty":-116.300053,"median":-57.849628,"eighty":-10.621478,"marketCap":775102137},{"date":"2022-11-25","current":12.407131,"twenty":-115.96534,"median":-14.923167,"eighty":-10.480819,"marketCap":745767849},{"date":"2022-12-02","current":12.125578,"twenty":-115.862351,"median":-14.830685,"eighty":-10.380046,"marketCap":728844222},{"date":"2022-12-09","current":11.731403,"twenty":-115.836604,"median":-14.696166,"eighty":-10.278552,"marketCap":705151143},{"date":"2022-12-16","current":11.787713,"twenty":-115.682121,"median":-14.628907,"eighty":-10.198952,"marketCap":708535869},{"date":"2022-12-23","current":10.098391,"twenty":-115.373154,"median":-14.612092,"eighty":-10.149379,"marketCap":606994104},{"date":"2022-12-30","current":9.854378,"twenty":-114.9612,"median":-14.570055,"eighty":-10.112039,"marketCap":592326960},{"date":"2023-01-06","current":8.897096,"twenty":-114.9612,"median":-14.498592,"eighty":-9.995706,"marketCap":534786627},{"date":"2023-01-13","current":9.347582,"twenty":-114.652234,"median":-14.469166,"eighty":-9.490104,"marketCap":561864431},{"date":"2023-01-20","current":8.44661,"twenty":-114.420509,"median":-14.460758,"eighty":-9.285179,"marketCap":507708823},{"date":"2023-01-27","current":8.089975,"twenty":-114.085795,"median":-14.343054,"eighty":-8.8279,"marketCap":486272228},{"date":"2023-02-03","current":7.789651,"twenty":-113.09208,"median":-14.29261,"eighty":-8.66047,"marketCap":468220359},{"date":"2023-02-10","current":7.414246,"twenty":-112.402996,"median":-14.124462,"eighty":-8.521406,"marketCap":445655522},{"date":"2023-02-17","current":6.90745,"twenty":-112.126803,"median":-14.057202,"eighty":-8.389413,"marketCap":415192993},{"date":"2023-02-24","current":7.864732,"twenty":-111.846305,"median":-13.83861,"eighty":-8.243997,"marketCap":472733326},{"date":"2023-03-03","current":7.526868,"twenty":-111.463864,"median":-13.785307,"eighty":7.425509,"marketCap":452424973},{"date":"2023-03-10","current":8.46538,"twenty":-111.107035,"median":-13.334165,"eighty":7.560655,"marketCap":508837065},{"date":"2023-03-17","current":7.71457,"twenty":-110.83275,"median":-13.115572,"eighty":7.673276,"marketCap":463707392},{"date":"2023-03-24","current":8.972177,"twenty":-110.712913,"median":-12.947423,"eighty":7.744603,"marketCap":539299594},{"date":"2023-03-31","current":8.46538,"twenty":-110.706407,"median":-12.821312,"eighty":7.819684,"marketCap":508837065},{"date":"2023-04-06","current":8.840785,"twenty":-110.58865,"median":-12.594312,"eighty":7.879748,"marketCap":531401901},{"date":"2023-04-14","current":8.634312,"twenty":-110.091866,"median":-12.27483,"eighty":8.048681,"marketCap":518991241},{"date":"2023-04-21","current":9.19742,"twenty":-109.828492,"median":-12.195568,"eighty":8.086221,"marketCap":552838496},{"date":"2023-04-28","current":8.409069,"twenty":-109.760268,"median":-11.333473,"eighty":8.281432,"marketCap":505452339},{"date":"2023-05-05","current":8.559231,"twenty":-109.528543,"median":-11.241206,"eighty":8.405315,"marketCap":514478274},{"date":"2023-05-12","current":8.507613,"twenty":-109.425554,"median":-11.225828,"eighty":8.461626,"marketCap":511375609},{"date":"2023-05-19","current":11.961379,"twenty":-109.425554,"median":-11.225828,"eighty":8.48415,"marketCap":508837065},{"date":"2023-05-26","current":11.27181,"twenty":-109.425554,"median":-11.118183,"eighty":8.518875,"marketCap":479502777},{"date":"2023-06-02","current":12.067467,"twenty":-109.425554,"median":-10.99516,"eighty":8.545154,"marketCap":513350032},{"date":"2023-06-09","current":14.933211,"twenty":-109.425554,"median":-10.85676,"eighty":8.559231,"marketCap":488539994},{"date":"2023-06-16","current":15.174275,"twenty":-109.425554,"median":-10.764492,"eighty":8.634312,"marketCap":496426405},{"date":"2023-06-23","current":14.725944,"twenty":-109.425554,"median":-10.764492,"eighty":8.664345,"marketCap":481759261},{"date":"2023-06-30","current":13.794795,"twenty":-109.425554,"median":-10.749115,"eighty":8.724409,"marketCap":451296732},{"date":"2023-07-07","current":13.518899,"twenty":-109.425554,"median":-10.718359,"eighty":8.833277,"marketCap":442270797},{"date":"2023-07-14","current":13.96723,"twenty":-109.425554,"median":-10.708286,"eighty":8.915866,"marketCap":456937941},{"date":"2023-07-21","current":14.346587,"twenty":-109.156415,"median":-10.656848,"eighty":9.099815,"marketCap":469348601},{"date":"2023-07-28","current":13.484413,"twenty":-108.752706,"median":-10.639547,"eighty":9.219944,"marketCap":441142555},{"date":"2023-08-04","current":13.617877,"twenty":-108.661384,"median":-10.609791,"eighty":9.358844,"marketCap":445508851},{"date":"2023-08-11","current":13.760308,"twenty":-108.472908,"median":-10.46078,"eighty":9.465834,"marketCap":450168490},{"date":"2023-08-18","current":13.484413,"twenty":-108.344172,"median":-10.380046,"eighty":10.015802,"marketCap":441142555},{"date":"2023-08-25","current":13.449926,"twenty":-108.245248,"median":-10.341601,"eighty":11.332277,"marketCap":440014313},{"date":"2023-09-01","current":13.449926,"twenty":-108.169524,"median":-10.272401,"eighty":11.586733,"marketCap":440014313},{"date":"2023-09-08","current":6.269046,"twenty":-108.085673,"median":-10.235084,"eighty":11.483985,"marketCap":417449477},{"date":"2023-09-15","current":6.031838,"twenty":-108.006913,"median":-10.180134,"eighty":11.376333,"marketCap":401654091},{"date":"2023-09-22","current":5.981008,"twenty":-107.996729,"median":-10.149379,"eighty":11.363505,"marketCap":398269365},{"date":"2023-09-29","current":6.060812,"twenty":-107.896286,"median":-10.136302,"eighty":11.334752,"marketCap":403583385},{"date":"2023-10-06","current":5.845461,"twenty":-107.486961,"median":-10.087867,"eighty":11.314244,"marketCap":389243431},{"date":"2023-10-13","current":4.93052,"twenty":-107.348748,"median":-9.980605,"eighty":11.067159,"marketCap":328318372},{"date":"2023-10-20","current":4.049465,"twenty":-106.916762,"median":-9.530373,"eighty":10.218521,"marketCap":269649797},{"date":"2023-10-27","current":5.049123,"twenty":-106.916762,"median":-9.519187,"eighty":10.158456,"marketCap":336216065},{"date":"2023-11-03","current":4.87969,"twenty":-106.799964,"median":-9.305964,"eighty":9.974508,"marketCap":324933647},{"date":"2023-11-10","current":4.583181,"twenty":-106.7093,"median":-9.161239,"eighty":9.869394,"marketCap":305189415},{"date":"2023-11-17","current":4.032521,"twenty":-106.63597,"median":-8.825662,"eighty":9.741757,"marketCap":268521555},{"date":"2023-11-24","current":4.811916,"twenty":-106.549573,"median":-8.747362,"eighty":9.587841,"marketCap":320420679},{"date":"2023-12-01","current":4.201955,"twenty":-106.476716,"median":-8.614026,"eighty":9.465834,"marketCap":279803973},{"date":"2023-12-08","current":5.286161,"twenty":-106.464627,"median":-8.557201,"eighty":9.460203,"marketCap":352000168},{"date":"2023-12-15","current":5.03218,"twenty":-106.429487,"median":-8.434157,"eighty":9.430171,"marketCap":335087823},{"date":"2023-12-22","current":5.659084,"twenty":-106.360423,"median":-8.389413,"eighty":9.377614,"marketCap":376832771},{"date":"2023-12-29","current":8.947611,"twenty":-106.352246,"median":-8.389413,"eighty":9.37386,"marketCap":467092117},{"date":"2024-01-05","current":9.077286,"twenty":-106.310144,"median":-8.34467,"eighty":9.362598,"marketCap":473861568},{"date":"2024-01-12","current":9.876952,"twenty":-106.154682,"median":3.744484,"eighty":9.445187,"marketCap":515606516},{"date":"2024-01-19","current":9.206962,"twenty":-105.944791,"median":4.015578,"eighty":9.460203,"marketCap":480631019},{"date":"2024-01-26","current":8.882773,"twenty":-105.865954,"median":4.07488,"eighty":9.460203,"marketCap":463707392},{"date":"2024-02-02","current":7.922526,"twenty":-105.836795,"median":4.201955,"eighty":9.385122,"marketCap":413579607},{"date":"2024-02-09","current":7.326667,"twenty":-105.512804,"median":4.273964,"eighty":9.379862,"marketCap":382473980},{"date":"2024-02-16","current":7.715693,"twenty":-105.296811,"median":4.303615,"eighty":9.366352,"marketCap":402782333},{"date":"2024-02-23","current":7.725203,"twenty":-105.296811,"median":4.337502,"eighty":9.351336,"marketCap":403278759},{"date":"2024-03-01","current":6.310875,"twenty":-105.210413,"median":4.489992,"eighty":9.304246,"marketCap":329446614},{"date":"2024-03-08","current":6.570226,"twenty":-104.870611,"median":4.676369,"eighty":9.291699,"marketCap":342985516},{"date":"2024-03-15","current":6.786352,"twenty":-104.688071,"median":4.752614,"eighty":9.291271,"marketCap":354267934},{"date":"2024-03-22","current":6.710708,"twenty":-104.565132,"median":4.811916,"eighty":9.258404,"marketCap":350319088},{"date":"2024-03-28","current":6.008299,"twenty":-104.34644,"median":4.811916,"eighty":9.250187,"marketCap":313651228},{"date":"2024-04-05","current":6.159587,"twenty":-104.216844,"median":4.845802,"eighty":9.241051,"marketCap":321548921},{"date":"2024-04-12","current":5.815515,"twenty":-104.216844,"median":4.896633,"eighty":9.218161,"marketCap":303587311},{"date":"2024-04-19","current":5.835398,"twenty":-104.175166,"median":4.938992,"eighty":9.201237,"marketCap":304625294},{"date":"2024-04-26","current":5.893968,"twenty":-103.992897,"median":5.015236,"eighty":9.190177,"marketCap":307682829},{"date":"2024-05-03","current":6.418938,"twenty":-103.762079,"median":5.057595,"eighty":9.181329,"marketCap":335087823},{"date":"2024-05-10","current":5.965074,"twenty":-103.495723,"median":5.08301,"eighty":9.178649,"marketCap":311394745},{"date":"2024-05-17","current":5.576047,"twenty":-103.297723,"median":5.193142,"eighty":9.156125,"marketCap":291086392},{"date":"2024-05-24","current":5.640885,"twenty":-103.246229,"median":5.286161,"eighty":9.12875,"marketCap":294471117},{"date":"2024-05-31","current":5.662498,"twenty":-103.14324,"median":5.420183,"eighty":9.103221,"marketCap":295599359},{"date":"2024-06-07","current":5.878623,"twenty":-102.988757,"median":5.554435,"eighty":9.072964,"marketCap":306881777},{"date":"2024-06-14","current":5.554435,"twenty":-102.988757,"median":5.586854,"eighty":9.060759,"marketCap":289958150},{"date":"2024-06-21","current":5.673304,"twenty":-102.988757,"median":5.619272,"eighty":9.037873,"marketCap":296163480},{"date":"2024-06-28","current":5.424759,"twenty":-102.918409,"median":5.619272,"eighty":9.019103,"marketCap":283188699},{"date":"2024-07-05","current":5.403147,"twenty":-102.770819,"median":5.608466,"eighty":8.987193,"marketCap":282060457},{"date":"2024-07-12","current":5.424759,"twenty":-102.525307,"median":5.554435,"eighty":8.967264,"marketCap":283188699},{"date":"2024-07-15","current":5.554435,"twenty":-102.448066,"median":5.554435,"eighty":8.962351,"marketCap":289958150},{"date":"2024-08-02","current":5.208633,"twenty":-102.370824,"median":5.554435,"eighty":8.957437,"marketCap":271906281},{"date":"2024-08-09","current":4.387355,"twenty":-101.907375,"median":5.43179,"eighty":8.928564,"marketCap":229033091},{"date":"2024-08-16","current":4.171229,"twenty":-101.525916,"median":5.424759,"eighty":8.915866,"marketCap":217750673},{"date":"2024-08-23","current":4.322517,"twenty":-101.084939,"median":5.413502,"eighty":8.908977,"marketCap":225648366},{"date":"2024-08-30","current":4.257679,"twenty":-100.804147,"median":5.403147,"eighty":8.900012,"marketCap":222263640},{"date":"2024-09-06","current":3.976716,"twenty":-100.467701,"median":5.403147,"eighty":8.891367,"marketCap":207596496},{"date":"2024-09-13","current":3.976716,"twenty":-66.285269,"median":5.269303,"eighty":8.880994,"marketCap":207596496},{"date":"2024-09-20","current":3.890265,"twenty":-15.382212,"median":5.208633,"eighty":8.863309,"marketCap":203083529},{"date":"2024-09-27","current":4.668319,"twenty":-14.928211,"median":5.142312,"eighty":8.833277,"marketCap":243700235},{"date":"2024-10-04","current":4.841219,"twenty":-14.891218,"median":5.08301,"eighty":8.814418,"marketCap":252726169},{"date":"2024-10-11","current":4.234044,"twenty":-14.860951,"median":5.040652,"eighty":8.795603,"marketCap":221029795},{"date":"2024-10-18","current":4.408968,"twenty":-14.803781,"median":4.964406,"eighty":8.780568,"marketCap":230161333},{"date":"2024-10-25","current":4.063166,"twenty":-14.736522,"median":4.922048,"eighty":8.77471,"marketCap":212109464},{"date":"2024-10-31","current":3.890265,"twenty":-14.696166,"median":4.888161,"eighty":8.769155,"marketCap":203083529},{"date":"2024-11-08","current":3.609302,"twenty":-14.68944,"median":4.841219,"eighty":8.739426,"marketCap":188416385},{"date":"2024-11-15","current":1.718201,"twenty":-14.655811,"median":4.835039,"eighty":8.705166,"marketCap":89695225},{"date":"2024-11-22","current":2.398997,"twenty":-14.625544,"median":4.811916,"eighty":8.684979,"marketCap":125234843},{"date":"2024-11-29","current":3.2635,"twenty":-14.612092,"median":4.811916,"eighty":8.671853,"marketCap":170364516},{"date":"2024-12-06","current":3.209469,"twenty":-14.612092,"median":4.777205,"eighty":8.671853,"marketCap":167543911},{"date":"2024-12-13","current":5.057345,"twenty":-14.612092,"median":4.811916,"eighty":8.662468,"marketCap":264008588},{"date":"2024-12-20","current":5.273471,"twenty":-14.595277,"median":4.811916,"eighty":8.653083,"marketCap":275291006},{"date":"2024-12-27","current":5.338309,"twenty":-14.554922,"median":4.824233,"eighty":8.638066,"marketCap":278675732},{"date":"2025-01-03","current":5.035733,"twenty":-14.524655,"median":4.841219,"eighty":8.634312,"marketCap":262880346},{"date":"2025-01-10","current":3.630914,"twenty":-14.501114,"median":4.835039,"eighty":8.634312,"marketCap":189544627},{"date":"2025-01-17","current":3.782203,"twenty":-14.482618,"median":4.811916,"eighty":8.612764,"marketCap":197442320},{"date":"2025-01-24","current":3.587689,"twenty":-14.475892,"median":4.811916,"eighty":8.579954,"marketCap":187288143},{"date":"2025-01-31","current":3.436401,"twenty":-14.467484,"median":4.777205,"eighty":8.574248,"marketCap":179390450}],"updateTime":1755544631507},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PROC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2558666586","title":"Sonnet Releases Virtual Investor \"What This Means\" Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2558666586","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558666586?lang=en_us&edition=fundamental","pubTime":"2025-08-11 21:15","pubTimestamp":1754918100,"startTime":"0","endTime":"0","summary":"- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) -Watch the \"Wh","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3130984/0/en/Sonnet-Releases-Virtual-Investor-What-This-Means-Segment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","TME","BK4007","BK4531","SG9999011746.SGD","BK4563","IE00BYQNZ168.SGD","LU2039709279.SGD","LU0359202008.SGD","LU1023057109.AUD","BK4139","01698","BK4108","BK4552","BK4571","IE00B12V2V27.USD","BK4509","BK4231","BK4548","IE00BYTNYN87.SGD","BK4526","PROC","SRC","SONN","BK4080","BK4565","BK4535"],"gpt_icon":0},{"id":"2557935563","title":"Immunocore reports second quarter financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557935563","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557935563?lang=en_us&edition=fundamental","pubTime":"2025-08-07 19:00","pubTimestamp":1754564400,"startTime":"0","endTime":"0","summary":"KIMMTRAK (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Ph","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129043/0/en/Immunocore-reports-second-quarter-financial-results-and-provides-a-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4147","IE00BYQQ9H92.USD","OS","LU1721428933.USD","LU1878469433.USD","PFS","LU0963586101.USD","BK4007","ALT","IE00B19Z4B17.USD","BK4599","MTD","BK4097","CTA","BK4211","BK4006","LU2413666699.HKD","CM","LU2065731478.USD","BK4533","CRS","IE00BFXG0V08.USD","BK4588","LU1093756168.USD","LU2211817866.USD","PROC","IE0031619046.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","ATOM","BK4139","BK4207","BK4585","BK4567","ORR","LU2413666426.HKD","LU1093756325.SGD","BK4548","LU0347712357.USD","BK4121"],"gpt_icon":0},{"id":"2557776307","title":"Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2557776307","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557776307?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:05","pubTimestamp":1754510700,"startTime":"0","endTime":"0","summary":"DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated appro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128670/0/en/Zentalis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","BK4097","BK4007","BK4231","ADC","LU2065732104.USD","PROC","BK4080"],"gpt_icon":0},{"id":"2556384832","title":"Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2556384832","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556384832?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:40","pubTimestamp":1754311200,"startTime":"0","endTime":"0","summary":"Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/04/3126587/0/en/Sonnet-BioTherapeutics-Expands-Clinical-Evaluation-of-SON-1010-Dose-Escalation-with-Atezolizumab-in-Ovarian-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TME","BK4563","IE00BYQNZ168.SGD","LU0359202008.SGD","01698","BK4136","BK4231","BK4108","BK4535","BK4548","PR","BK4213","SRC","BK4571","IE00B12V2V27.USD","BK4531","LU1023057109.AUD","IE00BYTNYN87.SGD","LU2039709279.SGD","SONN","BK4080","BK4139","BK4552","SG9999011746.SGD","PROC","SON","LU0359201612.USD","BK4007","BK4565","BK4509","BK4526"],"gpt_icon":0},{"id":"2532077369","title":"Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2532077369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532077369?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., May 01, 2025  -- Sonnet BioTherapeutics Holdings, Inc.  , a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment , today announced it will present at the 6th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.Title: Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeutic WindowSession: Understanding Toxicity Challenges & Improving Safety Profiles to Widen the Therapeutic WindowSpeaker: Richard Kenney, M.D., Chief Medical Officer of Sonnet Date and Time: Thursday, May 15, 2025 at 11:15 AM ET. Exploring the strategy behind the introduction of receptor bias to reduce toxicity and improve efficacy;Key strategies for optimizing cytokine potency and mitigating their inherent toxicity while considering the role of the therapeutic index in determining the clinical efficacy and safety of cytokine-based therapies; and. Examining whether toxicity is the primary limiting fac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sonnet-chief-medical-officer-richard-130000304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMMF","BK4565","BK4535","BK4007","BK4548","BK4108","IE00BYTNYN87.SGD","BK4509","LU0359201612.USD","SONN","BK4531","SG9999011746.SGD","LU1023057109.AUD","TME","BK4526","BK4552","IE00B12V2V27.USD","BK4571","BK4563","BK4211","01698","IE00BYQNZ168.SGD","PROC","LU0359202008.SGD","BK4139","LU2039709279.SGD"],"gpt_icon":0},{"id":"2530054444","title":"Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC","url":"https://stock-news.laohu8.com/highlight/detail?id=2530054444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530054444?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms. Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback. SAN DIEGO, April 28, 2025  -- Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial  of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer .As previously disclosed, the Company aligned with the U.S. Food and Drug Administration  on the design of DENALI Part 2, which allows for seamless enrollment in the two parts of the trial:. Part 2b is designed to enroll approximately 70 additional patients at the selected dose, which will be informed by the Part 2a results, subject to FDA feedback.Azenosertib is a n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zentalis-pharmaceuticals-announces-first-patient-120000488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PROC","ZNTL","ORR","BK4007"],"gpt_icon":0},{"id":"2530184200","title":"AbbVie Reports First-Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530184200","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530184200?lang=en_us&edition=fundamental","pubTime":"2025-04-25 19:43","pubTimestamp":1745581380,"startTime":"0","endTime":"0","summary":"Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense. Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis. First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues Were $1.121 Billion. First-Quarter Global Net Revenues from the Oncology Portfolio Were $1.633 Billion, an Increase of 5.8 Percent on a Reported Basis, or 7.5 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $738 Million; Global Venclexta Net Revenues Were $665 Million; Global El","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-reports-first-quarter-2025-114300471.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-reports-first-quarter-2025-114300471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","EC","LU2237443978.SGD","IE00BDGV0183.EUR","IE0004445239.USD","LU1839511570.USD","PFS","IE00B19Z3581.USD","LU1244550221.USD","SG9999015978.USD","LU2129689431.USD","IE00BJT1NW94.SGD","LU2089283258.USD","LU2129689514.USD","LU1093756325.SGD","IE0002141913.USD","CEO","BK4588","LU0114720955.EUR","LU0456855351.SGD","LU1093756168.USD","LU2237443895.HKD","LU2237443549.SGD","LU1929549753.HKD","LU2468319806.SGD","LU0128525929.USD","LU0965508806.USD","LU1989772840.SGD","LU0310799852.SGD","LU1244550494.USD","LU0310800379.SGD","LU0203347892.USD","BK4581","BK4534","LU0708994859.HKD","LU0029864427.USD","BK4566","LU2237443465.HKD","OS","SG9999015986.USD","ABBV","LU0882574055.USD","BK4559","BK4211","BK4201","PROC","IE00BVYPNV92.GBP","LU1496350502.SGD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2529319666","title":"Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529319666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529319666?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:05","pubTimestamp":1745438700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 23, 2025  -- Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology  Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL.The poster will include clinical data as of an April 4, 2025 data cutoff from the Company’s ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant colorectal cancer.Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zentalis-pharmaceuticals-announces-poster-presentation-200500857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZNTL","PROC","BK4007","BK4139"],"gpt_icon":0},{"id":"2529565826","title":"Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529565826","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529565826?lang=en_us&edition=fundamental","pubTime":"2025-04-24 00:55","pubTimestamp":1745427315,"startTime":"0","endTime":"0","summary":"We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Corcept Therapeutics Incorporated  stands against other Guru stocks to invest in.The market uncertainty is reflected in ETFs as well, which are often considered wiser investment options due to active management strategies and lower risk compared to individual investing. For example, the Guru ETF is down 8.30% year-to-date as of April 18. However, over the last 12 months, the fund has posted share price returns of 13.38%. Similarly, five-year share returns stand at an impressive 51.57%. GURU gives retail investors a way to tap into the top stock picks of major hedge funds at a relatively low 0.75%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-incorporated-cort-among-165515574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","BK4007","QLD","TQQQ","NVIW.SI","TSYW.SI","LU1559883803.SGD","LU0566484027.USD","MNQmain","BK4532","PROC","PSQ","CORT","SQQQ","USJW.SI",".IXIC","NQmain","QID"],"gpt_icon":1},{"id":"2527248858","title":"Sonnet Releases Virtual Investor \"What This Means\" Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2527248858","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527248858?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:10","pubTimestamp":1744809000,"startTime":"0","endTime":"0","summary":"- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010. PRINCETON, N.J., April 16, 2025  -- Sonnet BioTherapeutics Holdings, Inc.  , a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment , today announced that members of the Sonnet management team participated in a Virtual Investor \"What This Means\" segment.As part of the segment, Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, discussed the recently announced positive safety results of SON-1010  at the highest dose combined with atezolizumab being evaluated in the Phase 1b/2a clinical trial in adult patients with advanced solid tumors or platinum-resistant ovarian cancer  . Mr. Rao and Dr. Kenney also provided insight into next steps for the program.The Virtual Investor \"What This Means\" segment featuring Sonnet is now available here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sonnet-releases-virtual-investor-means-131000302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4552","IE00B12V2V27.USD","BK4571","BK4007","LU0359201612.USD","LU0359202008.SGD","IE00BYTNYN87.SGD","BK4563","LU1023057109.AUD","SG9999011746.SGD","PROC","BK4509","BK4531","BK4565","TME","IE00BYQNZ168.SGD","01698","BK4548","LU2039709279.SGD","SONN","BK4526","BK4108","BK4535"],"gpt_icon":0},{"id":"2524017002","title":"Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2524017002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524017002?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:00","pubTimestamp":1743771600,"startTime":"0","endTime":"0","summary":"Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3055960/0/en/Sonnet-s-SON-1010-Demonstrates-a-Strong-Safety-Profile-in-Combination-with-Atezolizumab-for-Treatment-of-Platinum-Resistant-Ovarian-Cancer-Including-a-Partial-Response-at-the-Highe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4108","BK4548","IE00BYTNYN87.SGD","LU0359201612.USD","LU0359202008.SGD","LU2413666699.HKD","BK4121","PD","PROC","SRC","PR","SG9999011746.SGD","BK4136","BK4213","SD","IE00B12V2V27.USD","BK4509","BK4563","BK4533","BK4526","BK4552","LU1169589451.USD","BK4531","BK4139","BK4231","BK4218","IE00BFXG0V08.USD","BK4007","BK4565","LU1721428933.USD","SONN","LU1023057109.AUD","BK4181","LU1169590202.USD","IE00BYQQ9H92.USD","BK4571","PK","LU2039709279.SGD","MTD","BK4080","LU1093756168.USD","BK4585","SON","BK4567","BK4588","TME","01698","LU1093756325.SGD","BK4023"],"gpt_icon":0},{"id":"2524122631","title":"Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524122631","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524122631?lang=en_us&edition=fundamental","pubTime":"2025-04-02 05:30","pubTimestamp":1743543000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  01, 2025  (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053843/0/en/Zentalis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD",".IXIC","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","PROC","IE00B3QW5Z07.USD","NDAQ","IE00BKPKM429.USD","BK4112","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"2524435129","title":"Sonnet Announces Release of Corporate Update Video","url":"https://stock-news.laohu8.com/highlight/detail?id=2524435129","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524435129?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:15","pubTimestamp":1743538500,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., April 01, 2025  -- Sonnet BioTherapeutics Holdings, Inc.  , a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment , today announced the release of a corporate update video. Access the video here.The corporate update video is also accessible on the Events page under the Investors section of the Company’s website .Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB , the technology utilizes a fully human single chain antibody fragment  that binds to and \"hitch-hikes\" on human serum albumin  for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sonnet-announces-release-corporate-video-201500252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["01698","LU0359201612.USD","SONN","BK4535","TME","SG9999011746.SGD","BK4139","LU1023057109.AUD","BK4108","BK4548","BK4563","PROC","IE00BYTNYN87.SGD","LU2039709279.SGD","BK4571","LU0359202008.SGD","BK4526","IE00BYQNZ168.SGD","BK4531","BK4552","BK4565","IE00B12V2V27.USD","BK4509","BK4007"],"gpt_icon":0},{"id":"2524978841","title":"Press Release: Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524978841","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524978841?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:30","pubTimestamp":1743507000,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., April 01, 2025  -- Sonnet BioTherapeutics Holdings, Inc.  , a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment , today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends to launch a CEO search.Mr. Rao, Interim CEO, commented, \"We are heartbroken by this unexpected, tragic loss. Pankaj was a respected leader and visionary throughout his ten years at Sonnet. His unwavering belief in Sonnet's technology and dedication to providing much needed treatment options to patients has continued to propel Sonnet to where it is today. Our s","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4563","BK4526","SONN","H","BK4142","LU0359201612.USD","LU0359202008.SGD","PROC","BK4585","LU2039709279.SGD","BK4535","IE00B12V2V27.USD","IE00BYTNYN87.SGD","BK4565","R","BK4232","TME","SG9999011746.SGD","BK4509","01698","BK4548","BK4571","LU1023057109.AUD","BK4531","BK4139","BK4552","IE00BYQNZ168.SGD","BK4108","BK4007"],"gpt_icon":0},{"id":"2522304123","title":"Press Release: Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304123","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304123?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer . Topline data from registration-intent DENALI Part 2 anticipated by year end 2026. Strengthened management team to support execution of highly focused strategy. $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027. \"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of azenosertib,\" said Julie Eastland, Chief Executive Officer of Zentalis. \"The clinical data we recently presented supports rapid advancement of azenosertib as a monotherapy therapy for patients with Cyclin E1+ PROC, and the continued development of azenosertib in other settings of ovarian cancer and other tumor types. With a sharpened focus on clinical developme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ORR","ADC","PROC","BK4007","ZNTL","BK4022","BK4139","R","BK4080","BK4232"],"gpt_icon":1},{"id":"2522234805","title":"Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2522234805","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522234805?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:05","pubTimestamp":1742994300,"startTime":"0","endTime":"0","summary":"SON-1010 is being studied as a combination therapy with trabectedin (Yondelis), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/26/3049745/0/en/Sonnet-BioTherapeutics-Successfully-Completes-First-Safety-Review-of-SON-1010-in-Combination-with-Trabectedin-in-Certain-Sarcomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4136","SG9999011746.SGD","BK4552","BK4108","BK4509","BK4571","IE00BYQNZ168.SGD","BK4023","BK4211","BK4121","BK4563","01698","LU2413666699.HKD","LU2413666426.HKD","LU0359201612.USD","BK4533","PK","BK4007","BK4526","BK4567","PD","IE00BYTNYN87.SGD","IE00B12V2V27.USD","BK4195","PR","LU1721428933.USD","LU0347712357.USD","LU1023057109.AUD","SON","LU1093756168.USD","SONN","PROC","LU2039709279.SGD","BK4139","BK4548","BK4531","BK4213","IE00BFXG0V08.USD","LU0359202008.SGD","MTD","BK4585","PFS","BK4588","SRC","IE00BYQQ9H92.USD","BK4218","BK4181","BK4080"],"gpt_icon":1},{"id":"2522283381","title":"Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522283381","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522283381?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:40","pubTimestamp":1742935200,"startTime":"0","endTime":"0","summary":"One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3049204/0/en/Zentalis-Pharmaceuticals-to-Present-Multiple-Posters-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4117","PROC","BK4107","AFG"],"gpt_icon":0},{"id":"2522059071","title":"Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522059071","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522059071?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:30","pubTimestamp":1742898600,"startTime":"0","endTime":"0","summary":"Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis. Continued demonstration of favorable tolerability profile generally consistent with previously reported data; over 800 patients treated across the greater nemvaleukin clinical program. The company remains on track to share topline results from potentially registrational, phase 2 trial in mucosal melanoma, ARTISTRY-6, Cohort 2, evaluating nemvaleukin monotherapy in Q2 2025. Nemvaleukin is currently being evaluated in a potentially registrational, phase 2 trial, ARTISTRY-6, cohort 2 in mucosal melanoma, with a topline data readout expected in Q2 2025. Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma are expected in the second quarter of 2025 for cohort 3 of ARTISTRY-6  and the second half of 2025 for cohort 4 of ARTISTRY-6 , subject to patient enrollment.KEYTRUDA is a registered ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mural-oncology-provides-phase-3-103000352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999001440.SGD","SG9999014575.USD","LU1057294990.SGD","LU1066051225.USD","LU1066053197.SGD","LU1585245621.USD","LU1116320737.USD","MRK","SG9999002224.SGD","SG9999001176.USD","LU0203345920.USD","LU1941712348.USD","MURA","BK4550","LU2361045086.USD","SG9999014542.SGD","PROC","LU0211331839.USD","LU0006306889.USD","LU1116320901.HKD","IE00BLSP4452.SGD","LU0320765489.SGD","LU1066051498.USD","LU0861579265.USD","LU1066051811.HKD","SG9999015358.SGD","LU0234572021.USD","LU2112291526.USD","IE00B4R5TH58.HKD","LU1934455194.USD","LU0238689110.USD","LU1974910355.USD","IE00BN8TJ469.HKD","LU1929549753.HKD","LU1291159041.SGD","BK4533","IE0009355771.USD","LU0266013472.USD","SG9999015341.SGD","IE00BJJMRZ35.SGD","LU2361044865.SGD","LU1989772840.SGD","SG9999002232.USD","LU1989771016.USD","LU0122379950.USD","LU1069347547.HKD","IE00BJT1NW94.SGD","LU0058720904.USD","LU2461242641.AUD","BK4516"],"gpt_icon":1},{"id":"2521293715","title":"Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521293715","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521293715?lang=en_us&edition=fundamental","pubTime":"2025-03-22 11:29","pubTimestamp":1742614140,"startTime":"0","endTime":"0","summary":"Company Announcement  AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/22/3047383/0/en/Genmab-to-Vigorously-Defend-Alleged-Claims-of-Trade-Secret-Misappropriation-by-AbbVie-Inc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0211328371.USD","LU1929549753.HKD","LU0912757837.SGD","LU1267930573.SGD","LU1430594728.SGD","LU0310800379.SGD","LU1989771016.USD","LU1721429402.USD","IE00BDGV0183.EUR","BK4585","BK4533","DAR","SG9999015945.SGD","LU1718418525.SGD","LU0795875169.SGD","LU0256863902.USD","PROC","LU1585245621.USD","LU0689472784.USD","LU1496350171.SGD","LU1732799900.SGD","LU0553294199.USD","IE0009355771.USD","BK4588","LU1037948897.HKD","LU0170899867.USD","LU0211327993.USD","LU0661504455.SGD","ABBV","BK4007","SG9999001440.SGD","LU0882574055.USD","IE00BSNM7G36.USD","LU2211817866.USD","LU0949170772.SGD","LU0256331488.USD","LU2129689431.USD","LU2237443549.SGD","LU0861579265.USD","LU1003077747.HKD","LU1839511570.USD","LU0965509283.SGD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU0203345920.USD","IE00BVYPNW00.USD","LU1093756325.SGD","LU0708994859.HKD","LU1267930490.SGD"],"gpt_icon":0},{"id":"2521496943","title":"Press Release: MacroGenics Provides Update on Corporate Progress and 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496943","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496943?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:02","pubTimestamp":1742500920,"startTime":"0","endTime":"0","summary":"-- Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of. lorigerlimab in combination with docetaxel in patients with mCRPC. -- Initiating new LINNET Phase 2 study of lorigerlimab in ovarian cancer. -- Advancing multiple novel topoisomerase 1 inhibitor-based ADCs, including. -- Discontinuing further internal clinical development of vobra duo;-- Cash, cash equivalents and marketable securities of $201.7 million as of. December 31, 2024; cash runway extended into the second half of 2026. vs. docetaxel alone in second-line, chemotherapy-nave patients with. -- Based on MacroGenics' cumulative experience to date from its Phase 1 and. conduct the LINNET Phase 2 study. This clinical trial will evaluate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","MGNX","BK4231","BK4097","PROC","BK4139","BK4080","BK4007","PRGS","ADC","BK4022","R","LU2065732104.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}